Pirfenidone in idiopathic pulmonary fibrosis (IPF): Early Spanish experience with the European Named patient program (NPP)

M. A. Nieto Barbero, C. Valenzuela, P. Rivera Ortega, J. Zulueta Francés, S. C. Jaime, M. Manuela, M. R. Irene, H. Fernanda, G. S. Raquel, C. álvaro, P. Karina, S. Herrera, R. P. José Antonio, R. Ana, B. Eva, F. José Angel, L. Javier, M. Cristina, M. Amalia, Z. Miguel, B. Elena, Grupo EPID Futuro. SEPAR (Madrid, Navarra, Alicante, Valencia, Hospitalet de Llobregat, Barcelona, Coslada, Badalona, Sevilla, Granada, Zaragoza, San Sebastian, Oviedo, Sabadell, Laredo, León, Spain)

Source: Annual Congress 2013 –Diffuse parenchymal lung disease II
Session: Diffuse parenchymal lung disease II
Session type: Thematic Poster Session
Number: 2361
Disease area: Interstitial lung diseases

Congress or journal article abstractE-poster

Rating: 5
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. A. Nieto Barbero, C. Valenzuela, P. Rivera Ortega, J. Zulueta Francés, S. C. Jaime, M. Manuela, M. R. Irene, H. Fernanda, G. S. Raquel, C. álvaro, P. Karina, S. Herrera, R. P. José Antonio, R. Ana, B. Eva, F. José Angel, L. Javier, M. Cristina, M. Amalia, Z. Miguel, B. Elena, Grupo EPID Futuro. SEPAR (Madrid, Navarra, Alicante, Valencia, Hospitalet de Llobregat, Barcelona, Coslada, Badalona, Sevilla, Granada, Zaragoza, San Sebastian, Oviedo, Sabadell, Laredo, León, Spain). Pirfenidone in idiopathic pulmonary fibrosis (IPF): Early Spanish experience with the European Named patient program (NPP). Eur Respir J 2013; 42: Suppl. 57, 2361

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: